Moreover, several HER-targeted tyrosine kinase inhibitors (TKIs) including LAP and ERL are used to treat HER family overexpressing (or mutant) cancers and are being evaluated against ovarian cancer [50–53]. Here, CEBPB is linked to ovarian carcinoma.